A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis

Xiaoyan Xu, Yumeng Wang, Kamalika Mojumdar, Zhicheng Zhou, Kang Jin Jeong, Lingegowda S. Mangala, Shuangxing Yu, Yiu Huen Tsang, Cristian Rodriguez-Aguayo, Yiling Lu, Gabriel Lopez-Berestein, Anil K. Sood, Gordon B. Mills, Han Liang

Research output: Contribution to journalArticle

Abstract

Both miRNAs and A-to-I RNA editing, a widespread nucleotide modification mechanism, have recently emerged as key players in cancer pathophysiology. However, the functional impact of RNA editing of miRNAs in cancer remains largely unexplored. Here, we focused on an ADAR2-catalyzed RNA editing site within the miR-379-5p seed region. This site was under-edited in tumors relative to normal tissues, with a high editing level being correlated with better patient survival times across cancer types. We demonstrated that in contrast to wild-type miRNA, edited miR-379-5p inhibited cell proliferation and promoted apoptosis in diverse tumor contexts in vitro, which was due to the ability of edited but not wild-type miR-379-5p to target CD97. Importantly, through nanoliposomal delivery, edited miR-379-5p mimics significantly inhibited tumor growth and extended survival of mice. Our study indicates a role of RNA editing in diversifying miRNA function during cancer progression and highlights the translational potential of edited miRNAs as a new class of cancer therapeutics.

Original languageEnglish (US)
Pages (from-to)5343-5356
Number of pages14
JournalJournal of Clinical Investigation
Volume129
Issue number12
DOIs
StatePublished - Dec 2 2019

Fingerprint

MicroRNAs
Cell Proliferation
Apoptosis
RNA Editing
Neoplasms
Seeds
Nucleotides
Survival
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Xu, X., Wang, Y., Mojumdar, K., Zhou, Z., Jeong, K. J., Mangala, L. S., ... Liang, H. (2019). A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis. Journal of Clinical Investigation, 129(12), 5343-5356. https://doi.org/10.1172/JCI123396

A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis. / Xu, Xiaoyan; Wang, Yumeng; Mojumdar, Kamalika; Zhou, Zhicheng; Jeong, Kang Jin; Mangala, Lingegowda S.; Yu, Shuangxing; Tsang, Yiu Huen; Rodriguez-Aguayo, Cristian; Lu, Yiling; Lopez-Berestein, Gabriel; Sood, Anil K.; Mills, Gordon B.; Liang, Han.

In: Journal of Clinical Investigation, Vol. 129, No. 12, 02.12.2019, p. 5343-5356.

Research output: Contribution to journalArticle

Xu, X, Wang, Y, Mojumdar, K, Zhou, Z, Jeong, KJ, Mangala, LS, Yu, S, Tsang, YH, Rodriguez-Aguayo, C, Lu, Y, Lopez-Berestein, G, Sood, AK, Mills, GB & Liang, H 2019, 'A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis', Journal of Clinical Investigation, vol. 129, no. 12, pp. 5343-5356. https://doi.org/10.1172/JCI123396
Xu, Xiaoyan ; Wang, Yumeng ; Mojumdar, Kamalika ; Zhou, Zhicheng ; Jeong, Kang Jin ; Mangala, Lingegowda S. ; Yu, Shuangxing ; Tsang, Yiu Huen ; Rodriguez-Aguayo, Cristian ; Lu, Yiling ; Lopez-Berestein, Gabriel ; Sood, Anil K. ; Mills, Gordon B. ; Liang, Han. / A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis. In: Journal of Clinical Investigation. 2019 ; Vol. 129, No. 12. pp. 5343-5356.
@article{dbbda0eae8444b6a8cceb22b1bf00f95,
title = "A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis",
abstract = "Both miRNAs and A-to-I RNA editing, a widespread nucleotide modification mechanism, have recently emerged as key players in cancer pathophysiology. However, the functional impact of RNA editing of miRNAs in cancer remains largely unexplored. Here, we focused on an ADAR2-catalyzed RNA editing site within the miR-379-5p seed region. This site was under-edited in tumors relative to normal tissues, with a high editing level being correlated with better patient survival times across cancer types. We demonstrated that in contrast to wild-type miRNA, edited miR-379-5p inhibited cell proliferation and promoted apoptosis in diverse tumor contexts in vitro, which was due to the ability of edited but not wild-type miR-379-5p to target CD97. Importantly, through nanoliposomal delivery, edited miR-379-5p mimics significantly inhibited tumor growth and extended survival of mice. Our study indicates a role of RNA editing in diversifying miRNA function during cancer progression and highlights the translational potential of edited miRNAs as a new class of cancer therapeutics.",
author = "Xiaoyan Xu and Yumeng Wang and Kamalika Mojumdar and Zhicheng Zhou and Jeong, {Kang Jin} and Mangala, {Lingegowda S.} and Shuangxing Yu and Tsang, {Yiu Huen} and Cristian Rodriguez-Aguayo and Yiling Lu and Gabriel Lopez-Berestein and Sood, {Anil K.} and Mills, {Gordon B.} and Han Liang",
year = "2019",
month = "12",
day = "2",
doi = "10.1172/JCI123396",
language = "English (US)",
volume = "129",
pages = "5343--5356",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "12",

}

TY - JOUR

T1 - A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis

AU - Xu, Xiaoyan

AU - Wang, Yumeng

AU - Mojumdar, Kamalika

AU - Zhou, Zhicheng

AU - Jeong, Kang Jin

AU - Mangala, Lingegowda S.

AU - Yu, Shuangxing

AU - Tsang, Yiu Huen

AU - Rodriguez-Aguayo, Cristian

AU - Lu, Yiling

AU - Lopez-Berestein, Gabriel

AU - Sood, Anil K.

AU - Mills, Gordon B.

AU - Liang, Han

PY - 2019/12/2

Y1 - 2019/12/2

N2 - Both miRNAs and A-to-I RNA editing, a widespread nucleotide modification mechanism, have recently emerged as key players in cancer pathophysiology. However, the functional impact of RNA editing of miRNAs in cancer remains largely unexplored. Here, we focused on an ADAR2-catalyzed RNA editing site within the miR-379-5p seed region. This site was under-edited in tumors relative to normal tissues, with a high editing level being correlated with better patient survival times across cancer types. We demonstrated that in contrast to wild-type miRNA, edited miR-379-5p inhibited cell proliferation and promoted apoptosis in diverse tumor contexts in vitro, which was due to the ability of edited but not wild-type miR-379-5p to target CD97. Importantly, through nanoliposomal delivery, edited miR-379-5p mimics significantly inhibited tumor growth and extended survival of mice. Our study indicates a role of RNA editing in diversifying miRNA function during cancer progression and highlights the translational potential of edited miRNAs as a new class of cancer therapeutics.

AB - Both miRNAs and A-to-I RNA editing, a widespread nucleotide modification mechanism, have recently emerged as key players in cancer pathophysiology. However, the functional impact of RNA editing of miRNAs in cancer remains largely unexplored. Here, we focused on an ADAR2-catalyzed RNA editing site within the miR-379-5p seed region. This site was under-edited in tumors relative to normal tissues, with a high editing level being correlated with better patient survival times across cancer types. We demonstrated that in contrast to wild-type miRNA, edited miR-379-5p inhibited cell proliferation and promoted apoptosis in diverse tumor contexts in vitro, which was due to the ability of edited but not wild-type miR-379-5p to target CD97. Importantly, through nanoliposomal delivery, edited miR-379-5p mimics significantly inhibited tumor growth and extended survival of mice. Our study indicates a role of RNA editing in diversifying miRNA function during cancer progression and highlights the translational potential of edited miRNAs as a new class of cancer therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=85076017650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076017650&partnerID=8YFLogxK

U2 - 10.1172/JCI123396

DO - 10.1172/JCI123396

M3 - Article

C2 - 31682236

AN - SCOPUS:85076017650

VL - 129

SP - 5343

EP - 5356

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 12

ER -